What if I purchased Cibus securities? If you believe that you may have a potential claim against Cibus and would like to participate in the investigation or learn more about your legal rights and options, please contact Johnson Fistel, LLP at (619) 814-4471 or click here to join the investigation online. There is no cost or obligation to you. Click Here to Join the Investigation SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP is investigating potential violations ...

SAN DIEGO, May 15, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS) (the "Company"), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, applauds the Canadian Food Inspection Agency (CFIA), Animal Feed Division's publication of its updated feed guidelines clarifying requirements for new plant varieties developed using applications of gene editing. The guidelines confirm that CFIA intends to fol ...

SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (NASDAQ:CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that Rory Riggs, Co-Founder, Chief Executive Officer, and Chairman, and Peter Beetham, Co-Founder, President, and Chief Operating Officer, will host a presentation at the BMO Global Farm to Market Conference taking place May 15-16, 2024. Presentation detailsDa ...

Cibus, Inc. (NASDAQ:CBUS) Q1 2024 Results Conference Call May 9, 2024 4:30 PM ET Conference Call Participants Good afternoon, and welcome to the Cibus First Quarter 2024 Results Conference Call. [Operator Instructions] Please also note today's event is being recorded. Thank you, and good afternoon. This is Wade King, Chief Financial Officer of Cibus. I would like to thank you for taking time to join us for Cibus' First Quarter 2024 Financial Results and Corporate Update Conference Call and Webcast. With tha ...

Cibus (CBUS) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.01. This compares to loss of $5.45 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -10.89%. A quarter ago, it was expected that this developer and licensor of plant traits for seed companies would post a loss of $1.12 per share when it actually produced a loss of $1.16, delivering a surprise of -3.57%.Over the las ...

_____________________ FORM 10-Q or Commission file number 001-38161 Securities registered pursuant to Section 12(b) of the Act. Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes x No o If an emerging growth company, indicate by check mark if the reg ...

Important EU Parliament vote on gene editing continues global momentum for the approval of new genomic techniques (NGTs) as similar to conventional breeding Completed single cell regeneration platform for Wheat – with Canola & Rice, Cibus now has its semiautomated crop platform operational for 3 of the top 5 major crops Continued progress with customers toward commercializing Pod Shatter Reduction (PSR) trait in Canola Cibus was recognized by Fast Company as one of the world's most innovative companies of 2 ...

SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural biotechnology company that uses proprietary gene editing technologies to develop plant traits (or specific genetic characteristics) in seeds, today announced that the company will report first quarter 2024 financial results on Thursday, May 9, 2024. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates. Title: C ...

Cibus (CBUS) came out with a quarterly loss of $1.16 per share versus the Zacks Consensus Estimate of a loss of $1.12. This compares to loss of $3 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -3.57%. A quarter ago, it was expected that this genetically modified food company would post a loss of $1.18 per share when it actually produced a loss of $1.59, delivering a surprise of -34.75%.Over the last four quarters, the compan ...

Company Participants Bobby Burleson - Canaccord Genuity Sameer Joshi - H.C. Wainwright Conference Call Participants Before we begin the call, I'd like to remind everyone that statements made on the call and webcast, including those regarding future financial results and future operational goals and industry prospects are forward-looking and may be subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the call. With that, I would now like ...